The Patent Finder

Teva Pharmaceuticals Australia Pty Ltd.

13 patents currently held · Updated Nov 18, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Sep 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 28, 2027
    The maintenance fee for Interferon Alpha 2B Variants (US 10,544,199) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 12,410,256Antibodies That Specifically Bind to TL1A and Methods of Treating Gastrointestinal or Lung Diseases
In force
 · Medium confidence
In forceMedium confidence
US 9,611,322Fusions of antibodies to CD38 and attenuated interferon alpha
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,505,826Modified antibody with improved half-life
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,963,515Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,981,986Fusions of antibodies to CD38 and attenuated interferon alpha
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,822,422Antibodies against TL1a and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,117,975Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,636,334Combination of lenalidomide and polypeptide construct, and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,232,041Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 10,544,199Interferon Alpha 2B Variants
In force
 · Medium confidence
In forceMedium confidence
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 4 patents in force now held by others · 11 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 6 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited